Physician profile
Danielle Doyle
NPI 1588236319
$2,049.40
in general payments reported to CMS, 2019-2025
14 companies · $917 in 2025
The $917 reported for 2025 was more than what 84% of Gerontology (Nurse Practitioner) providers received nationally (typical 2025 total: $180).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $201 · 2023: $149 · 2024: $782 · 2025: $917.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,848.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,848.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $421.47 | 2023-2025 | Farxiga, Lokelma |
| Novartis Pharmaceuticals Corporation | $387.78 | 2023-2025 | |
| Boston Scientific Corporation | $284.74 | 2024-2025 | Watchman Flx, Latitude Communicator Power Supply |
| Atricure, INC. | $203.45 | 2025 | Atriclip Laa Exclusion System, Epi-Sense Guided Coagulation System With Visitrax |
| Medtronic, INC. | $170.97 | 2022 | |
| Pfizer INC. | $152.83 | 2022-2025 | |
| Impulse Dynamics (USA) INC. | $131.96 | 2023-2024 | Optimizer, Optimizer |
| Amgen INC. | $94.52 | 2025 | Repatha, Repatha |
| E.R. Squibb & Sons, L.L.C. | $67.38 | 2023-2025 | Camzyos |
| Heartflow, INC. | $49.03 | 2024 | |
| Abiomed | $29.45 | 2024 | Impella |
| Chiesi USA, INC. | $27.09 | 2025 | Juxtapid |
| Kiniksa Pharmaceuticals International, Plc | $15.94 | 2024 | Arcalyst |
| Esperion Therapeutics, INC. | $12.79 | 2023 | Nexletol |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Danielle Doyle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.